<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227173</url>
  </required_header>
  <id_info>
    <org_study_id>IM136-004</org_study_id>
    <nct_id>NCT02227173</nct_id>
  </id_info>
  <brief_title>A Phase 1 Drug-drug Interaction Study in Healthy Volunteers</brief_title>
  <acronym>DDI</acronym>
  <official_title>Effect of BMS-986020 on the Pharmacokinetics of Montelukast, Flurbiprofen, and Digoxin as Probe Substrates for CYP2C8, CYP2C9, and P-gp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      This is an open-label, single-sequence, drug-drug interaction study in healthy male and
      female subjects. There is no formal research hypothesis to be statistically tested. It is
      expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may
      increase the exposure of montelukast, flurbiprofen, and digoxin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (maximum observed plasma concentration, area under the concentration-time curve) for montelukast, flurbiprofen, and digoxin</measure>
    <time_frame>Predose and up to 168 hours post dose</time_frame>
    <description>Pharmacokinetic endpoints for montelukast, flurbiprofen, and digoxin with and without BMS-986020</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional pharmacokinetic parameters for montelukast, flurbiprofen, and digoxin.</measure>
    <time_frame>Predose and up to 168 hour post dose</time_frame>
    <description>Additional pharmacokinetic parameters for montelukast, flurbiprofen, digoxin, and with and without BMS-986020</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>From dosing (Day 1) to Day 21</time_frame>
    <description>Collection of adverse events and other physical parameters to assess safety</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Drug-drug Interaction Study</condition>
  <arm_group>
    <arm_group_label>Single-Sequence, A B C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A:
Single oral dose of montelukast, flurbiprofen, and digoxin on Day 1
Treatment B:
BMS-986020 orally twice daily (BID) on Day 8 through Day 10
Treatment C:
BMS-986020 orally BID, single oral dose of montelukast, flurbiprofen, and digoxin on Day 11; BMS-986020 BID on Day 12 through Day 17</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986020</intervention_name>
    <arm_group_label>Single-Sequence, A B C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <arm_group_label>Single-Sequence, A B C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen</intervention_name>
    <arm_group_label>Single-Sequence, A B C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <arm_group_label>Single-Sequence, A B C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female nonsmoking subjects ages 18 to 50 years, inclusive, with a
             body mass index of 18.0 to 32.0 kg/m2, inclusive

          -  Women of childbearing potential must agree to follow instructions for methods of
             contraception for the duration of the study

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of arrhythmias or palpitations associated with dizziness or fainting

          -  History of clinically relevant cardiac disease

        Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuel DeNoia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Development Solutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries, LLC d/b/a ICON Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

